Fresh Off BMS Deal, Leading Chinese CRO WuXi PharmaTech Outlines Plan To Expand Biologics Business To Keep Pace With Big Pharma

BEIJING - Betting on the belief that Big Pharma will speed up the transfer of research and manufacturing to China, leading contract research organization WuXi PharmaTech is expanding its chemistry services even while preparing to launch a new biologics testing and production center near its headquarters in Shanghai